Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Comparison of autologous platelet-rich plasma with autologous serum eye drop in corneal epithelial disorders

Search Title by author or title

Session Details

Session Title: Cornea Medical II

Session Date/Time: Tuesday 13/09/2016 | 08:00-10:30

Paper Time: 09:00

Venue: Hall C3

First Author: : S.Zarei-Ghanavati IRAN

Co Author(s): :    A. Eslampoor   A. Zarea                 

Abstract Details

Purpose:

To compare Autologous Platelet-Rich Plasma (APRP) with Autologous Serum Eye Drop(ASED) in corneal persistent epithelial defect(PED).

Setting:

Mashhad University of Medical Sciences, Mashhad, Iran

Methods:

Thirty five eyes of 32 patients with persistent epithelial defect at the Khatam-Al-Anbia eye hospital of Mashhad university of medical science between 2012 and 2014 enrolled in the study ,randomly. nineteen eyes treated by APRP and the other sixteen eyes treated by ASED 20 %. The treatment applied for patients with persistent epithelial defects that didn’t respond to any other conventional therapy. Patients examined before, one week and one month after the treatment. Examination included BCVA, symptoms (pain and photophobia) and slit lamp examination including defect size.

Results:

In APRP-treated group, 9 patients had complete healing, 6 ones had partial healing and treatment failed in two patients. In ASED group, 6 patients healed completely, 10 patients partially healed and no patient was failed to treat. There was no significant difference in BCVA, pain, photophobia and slit lamp parameters between two groups before and after treatment. The healing rate was faster in APRP group.

Conclusions:

ASED and APRP both are effective in corneal epithelial defect. This study showed no significant difference between these two medications.

Financial Disclosure:

NONE

Back to previous